Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study

被引：0

作者：

Chia, Stephen

Neven, Patrick

Ciruelos, Eva M.

Lerebours, Florence

Ruiz-Borrego, Manuel

Drullinsky, Pamela

Prat, Aleix

Park, Yeon Hee

Juric, Dejan

Turner, Nicholas C.

Chattar, Yogesh

Patino, Heather

Akdere, Murat

Rugo, Hope S.

机构：

[1] Univ British Columbia, Vancouver, BC, Canada

[2] Univ Hosp, Leuven, Belgium

[3] Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain

[4] PSL Res Univ, Inst Curie, St Cloud, France

[5] Hosp Virgen Rocio Sevilla, Seville, Spain

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Hosp Clin Barcelona, Barcelona, Spain

[8] Samsung Med Ctr, Seoul, South Korea

[9] Massachusetts Gen Hosp, Boston, MA USA

[10] Royal Marsden NHS Fdn Trust, London, England

[11] Inst Canc Res, London, England

[12] Novartis Healthcare Private Ltd, Hyderabad, India

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Novartis Pharma AG, Basel, Switzerland

[15] Univ Calif San Francisco, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1078

引用

页数：1

共 50 条

[21] Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
Burnette, Sarah E.
Poehlein, Emily
Lee, Hui-Jie
Force, Jeremy
Westbrook, Kelly
Moore, Heather N.
BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (02) : 369 - 376
[22] Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
Juric, Dejan
Turner, Nicholas
Prat, Aleix
Chia, Stephen
Ciruelos, Eva M.
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Lerebours, Florence
Bachelot, Thomas
Balbin, O. Alejandro
Joshi, Mukta
Roux, Estelle
Arce, Christina H.
Akdere, Murat
Rugo, Hope S.
CANCER RESEARCH, 2022, 82 (04)
[23] Analysis of subsequent therapy in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and-3
Masuda, Norikazu
Mukai, Hirofumi
Inoue, Kenichi
Rai, Yoshiaki
Ohno, Shinji
Ohtani, Shoichiro
Shimizu, Chikako
Hashigaki, Satoshi
Muramatsu, Yasuaki
Umeyama, Yoshiko
Iwata, Hiroji
Toi, Masakazu
BREAST CANCER, 2021, 28 (02) : 335 - 345
[24] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Masato Takahashi
Eriko Tokunaga
Joji Mori
Yoshinori Tanizawa
Jan-Stefan van der Walt
Tsutomu Kawaguchi
Matthew P. Goetz
Masakazu Toi
Breast Cancer, 2022, 29 : 174 - 184
[25] Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Takahashi, Masato
Tokunaga, Eriko
Mori, Joji
Tanizawa, Yoshinori
Van der Walt, Jan-Stefan
Kawaguchi, Tsutomu
Goetz, Matthew P.
Toi, Masakazu
BREAST CANCER, 2022, 29 (01) : 174 - 184
[26] Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
Sarah E. Burnette
Emily Poehlein
Hui-Jie Lee
Jeremy Force
Kelly Westbrook
Heather N. Moore
Breast Cancer Research and Treatment, 2023, 197 : 369 - 376
[27] Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
D. Bello Roufai
A. Gonçalves
T. De La Motte Rouge
S. Akla
C. Blonz
J. Grenier
J. Gligorov
M. Saghatchian
C. Bailleux
H. Simon
I. Desmoulins
Z. Tharin
E. Renaud
M. Bertho
M-A Benderra
S. Delaloge
L. Robert
P. Cottu
J. Y. Pierga
D. Loirat
A. Bertucci
B. Renouf
F. C. Bidard
F. Lerebours
Oncogene, 2023, 42 : 1417 - 1417
[28] Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Kim, Jee Hyun
Im, Seock-Ah
Sim, Sung Hoon
Bananis, Eustratios
Huang, Xin
Kim, Hyun Seon
Kim, Sung-Bae
JOURNAL OF BREAST CANCER, 2021, 24 (01) : 97 - 105
[29] Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study
Jiang, Zefei
Hu, Xichun
Zhang, Qingyuan
Sun, Tao
Yin, Yongmei
Li, Huiping
Yan, Min
Tong, Zhongsheng
Oppermann, Christina Pimentel
Liu, Yunpeng
Costa, Romulo
Li, Man
Chen, Xi
Cheng, Ying
Ouyang, Quchang
Liao, Ning
Wang, Xiaojia
Wu, Xinhong
Feng, Jifeng
Hegg, Roberto
Setty, Govindbabu Kanaka
Agarwal, Amit
Bajpai, Jyoti
Cheng, Jing
Girotto, Gustavo
Goswami, Chanchal
Hu, Wenjing
Huang, Jian
Portugal, M. A. Coccia
Yang, Jin
Zheng, Rongsheng
Franke, Fabio Andre
Liu, Qiang
Liu, Yunjiang
Lu, Yongkui
Souza, Cristiano
Yu, Shiying
Kilara, Nalini
Panchal, Harsha
Singh, Ashish
Nag, Shona
Liu, Jian
Rapoport, Bernardo
Tabane, Neonyana Keorapetse Rebecca
Wang, Hongxia
Wang, Ning
Han, Rubing
Zhang, Wanli
CANCER RESEARCH, 2021, 81 (04)
[30] PIK3CA registry: A noninterventional, descriptive, retrospective cohort study of PIK3CA mutations in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
Rajadurai, Pathmanathan
Semiglazova, Tatiana
Hegmane, Alinta
El Karak, Fadi
Chiu, Joanne W.
Gupta, Sudeep
Azim, Hamdy A.
Kitzen, Josef Jem
Arnaud, Antoine
Haftchenary, Sina
Wu, Jiwen
Menon-Singh, Lakshmi
Smith, LaTonya
Zhukova, Lyudmila
CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →